Drugs with this side effect
- 5-ASA: very rare, postmarketing, 0% - 7%
- 5-FU
- 5-aza-2'-deoxycytidine: 1.23% - 8.43%
- 5-azacytidine: common
- 6-mercaptopurine
- A77 1726: 13% - 13.1%
- Azarga
- BCNU: 1-10% - 10%
- CAS 76095-16-4
- CAS 76420-72-9: postmarketing
- CGP 19835A: common
- D-penicillamine
- DFMO: 1.3% - 2.5%
- Estrofem
- FAMP: 0% - 3%
- FTY720: common, 3.53% - 4%
- FdUrd
- Goserelin: 1-10%
- Implanon: postmarketing
- K779: 8% - 38%
- Kaluril
- L-Dmp: infrequent
- LMWH: postmarketing
- Leuprorelin
- LiOH
- Lisinopril: postmarketing, rare
- Lovaza
- Metrodin
- NTBC
- Nafarelin
- NuvaRing
- Octreotide: common, 1% - 3.51%
- Oestrogen: common
- Promacta
- SOM230: 12.2% - 12.5%
- SU5416
- Signifor: 12.2% - 12.5%
- Stalevo 50
- TPGS
- Triptorelin
- Trisequens
- UDCA: postmarketing, 5.28% - 5.3%
- VACV: postmarketing
- Zyprexa Relprevv: very rare
- abacavir
- abacavir-lamivudine: postmarketing
- acamprosate: infrequent
- acenocoumarol
- acetohydroxamic acid
- acitretin: postmarketing, 7-75%
- actinomycin D
- acyclovir: postmarketing, uncommon
- afatinib: 0% - 13%
- alendronate: postmarketing
- allopurinol
- alosetron: rare
- amantadine: very rare
- amiloride
- amiodarone
- amitriptyline
- amlodipine
- amlodipine besylate
- amoxapine: postmarketing
- amphetamine
- amphotericin B
- amsacrine
- anagrelide: 1-5%
- anastrozole
- anthracycline: 0% - 36%
- aprepitant: 11.9% - 24%
- aripiprazole
- atazanavir: postmarketing, uncommon
- atenolol
- atorvastatin
- auranofin
- axitinib: 0% - 32%
- azathioprine: rare
- baclofen: uncommon
- balsalazide: postmarketing
- benazepril
- benazeprilat
- betaine: postmarketing, uncommon
- betaxolol: postmarketing
- bexarotene: 3.57% - 11.3%
- bezafibrate
- bicalutamide: 1-5% - 4%
- bisoprolol: very rare, postmarketing
- bleomycin hydrochloride
- boceprevir: very common, 16% - 27%
- brinzolamide: postmarketing
- bromocriptine: postmarketing, uncommon
- budesonide
- bupropion: postmarketing, infrequent
- buspirone: infrequent
- busulfan
- cabazitaxel: 0%
- cabergoline: postmarketing
- cabozantinib: 0% - 16%
- capecitabine: 1% - 42%
- captopril
- carbamazepine: very rare, rare
- carbidopa
- carbimazole
- carboplatin: 2% - 3%
- carvedilol: postmarketing
- cefpodoxime
- celecoxib
- cerivastatin
- cetirizine
- cevimeline
- chlorambucil
- chloroquine
- choline theophyllinate
- ciclopirox: postmarketing, rare
- cidofovir: postmarketing, very common, 27%
- cilazapril: postmarketing
- ciprofloxacin
- cisplatin
- citalopram: postmarketing, infrequent, uncommon
- cladribine
- clindamycin phosphate
- clobetasol: postmarketing
- clobetasol propionate
- clofarabine: common
- clomiphene citrate: 0.3%
- clomipramine: very rare, infrequent
- clonazepam
- clonidine
- colchicine: postmarketing
- copolymer 1
- cyclobenzaprine: postmarketing
- cyclophosphamide
- cyproterone acetate
- cytarabine
- dabrafenib: very common, 0% - 22%
- dacarbazine: 1-10%
- dalteparin: postmarketing
- danazol
- darunavir
- dasatinib
- deferasirox: postmarketing
- degarelix
- delamanid
- delavirdine
- deprenyl: infrequent, 0%
- desipramine
- desogestrel
- desvenlafaxine
- dexamethasone
- dexrazoxane: 94% - 100%
- diclofenac: very rare, 0% - 2%
- didanosine: postmarketing
- diethylpropion
- diltiazem: postmarketing
- dipyridamole
- docetaxel: very rare, 0% - 98%
- donepezil: infrequent
- dorzolamide
- doxazosin: postmarketing
- doxepin
- doxorubicin: common, very common, 6.7% - 95.5%
- duloxetine: infrequent
- efavirenz
- eletriptan: rare
- eltrombopag
- entecavir: postmarketing, uncommon
- eribulin: 10% - 45%
- erlotinib
- eslicarbazepine acetate
- esomeprazole magnesium: postmarketing
- estradiol: postmarketing, uncommon
- estramustine: 1%
- estramustine phosphate
- etidronate: postmarketing
- etodolac: postmarketing
- etoposide: 33% - 8-66%
- etoposide phosphate
- etoricoxib
- everolimus: common
- exemestane: common, 2-5% - 15.1%
- exenatide: postmarketing, rare, 0% - 2.07%
- ezetimibe
- famotidine
- febuxostat
- felbamate
- fenofibrate: rare
- fenoprofen: postmarketing
- fentanyl
- flecainide: postmarketing
- fluconazole: postmarketing, rare
- fludarabine: 0% - 3%
- fluocinolone acetonide
- fluoxetine: infrequent, uncommon
- fluoxymesterone
- flurbiprofen
- fluvastatin: postmarketing
- fluvoxamine: rare, infrequent
- gabapentin: postmarketing, infrequent
- ganciclovir
- gefitinib: common, 1-10%
- gemcitabine: common, 0% - 92%
- gemfibrozil
- gentamicin
- glibenclamide
- gold sodium thiomalate
- granisetron: 3%
- guanfacine: postmarketing
- haloperidol
- heparin: postmarketing
- hepatitis B vaccines
- hydrochlorothiazide
- hydroxybutyrate
- hydroxychloroquine
- hydroxyurea: uncommon, 1-5%
- ibandronate
- ibuprofen
- idarubicin: 72% - 77%
- ifosfamide: 1-83% - 83%
- imatinib: common, 0% - 22.3%
- imipramine: very rare
- imiquimod: 0% - 1.4%
- indinavir: postmarketing
- indomethacin
- insulin detemir
- irinotecan: 16.8% - 72%
- itraconazole: postmarketing
- ixabepilone: 0% - 48%
- ketoconazole: postmarketing
- ketoprofen
- ketorolac
- ketorolac tromethamine
- lamivudine: postmarketing, common
- lamotrigine: infrequent
- lanreotide
- lansoprazole
- lapatinib: very common, 0% - 7%
- lasofoxifene: uncommon
- leflunomide: postmarketing, common, 1% - 17%
- lenalidomide: common
- lercanidipine
- letrozole: common, 2.09% - 3.43%
- leucovorin: 5% - 43%
- leuprorelin acetate: 1.7% - 42%
- levetiracetam: postmarketing
- levobunolol
- levodopa/carbidopa
- levonorgestrel
- lindane: postmarketing
- lithium
- lithium carbonate
- lomustine
- loratadine: postmarketing
- lorazepam
- losartan
- lovastatin: postmarketing
- loxapine
- maprotiline
- maraviroc
- meclofenamate: postmarketing
- medroxyprogesterone: 1.1%
- medroxyprogesterone acetate
- mefenamic acid
- mefloquine: postmarketing
- megestrol
- megestrol acetate
- meloxicam
- melphalan: common, very common
- memantine: infrequent
- mephenytoin
- mesna: 10.1% - 13%
- methimazole
- methotrexate: 1-10%
- methylphenidate: postmarketing, common
- methyltestosterone
- methysergide
- metoprolol: rare
- metyrapone
- mexiletine
- minocycline
- mirtazapine: postmarketing, infrequent
- misoprostol: postmarketing
- mitomycin C
- mitoxantrone: 0% - 61%
- moexiprilat
- mycophenolate mofetil
- mycophenolic acid: postmarketing
- nabumetone: postmarketing, 0.9%
- nadolol
- naltrexone
- nandrolone
- naproxen: postmarketing
- naratriptan: rare
- nefazodone: infrequent
- niacin
- nifedipine
- nilotinib: common, 0% - 14%
- nisoldipine
- nitrofurantoin
- nitrogen mustard
- norethisterone
- nortriptyline
- ofloxacin
- olanzapine: very rare, postmarketing, infrequent
- olmesartan: postmarketing
- olmesartan medoxomil
- olsalazine
- omeprazole: postmarketing, rare, uncommon
- orlistat
- oxaliplatin: common, very common, 0% - 44.1%
- oxaprozin
- oxcarbazepine: common
- oxymetholone
- paclitaxel: very common, 87% - 94%
- paliperidone: postmarketing
- palonosetron
- pamidronate
- pantoprazole: postmarketing
- paricalcitol
- paroxetine: infrequent, uncommon
- pazopanib: 0% - 12%
- pemetrexed: 6% - 42%
- pentosan polysulfate: 4%
- pentostatin
- pergolide: infrequent
- perindopril erbumine
- pilocarpine
- pirbuterol
- piroxicam
- pixantrone
- ponatinib
- posaconazole
- pramipexole
- pravastatin
- prazosin
- prednisone
- pregabalin: infrequent
- probenecid
- procarbazine
- progesterone: postmarketing
- propafenone: postmarketing
- propranolol: postmarketing
- propylthiouracil
- protriptyline
- pyridostigmine
- quinapril
- quinaprilat
- rabeprazole
- raltegravir
- raltitrexed: 4-5%
- ramipril
- ranitidine
- rasagiline
- regorafenib
- repaglinide
- retigabine
- retinoic acid: postmarketing, 13% - 14%
- ribavirin: very common, 17% - 36%
- rifapentine
- riluzole: 0% - 1.2%
- risperidone: postmarketing, infrequent
- rivastigmine: infrequent
- rofecoxib
- ropinirole: infrequent, frequent
- salmon calcitonin acetate: postmarketing
- samarium
- saquinavir: common
- selenium
- selenium sulfide
- sertraline: postmarketing, infrequent, uncommon, frequent
- sibutramine
- sildenafil
- simvastatin: postmarketing
- sitaxsentan
- sofosbuvir: common
- sorafenib: postmarketing, 0% - 27%
- sotalol: postmarketing
- sparfloxacin
- spinosad
- spironolactone
- strontium ranelate: postmarketing
- sulfasalazine
- sulindac
- sunitinib
- tacrolimus: common, 0% - 1%
- tamoxifen: 5% - 5.2%
- tegaserod: postmarketing
- temazepam
- temozolomide: common, very common, 0% - 69.1%
- teniposide: 9%
- terbinafine: postmarketing
- testolactone
- testosterone: postmarketing, 0% - 1%
- testosterone enanthate: postmarketing
- testosterone propionate
- testosterone undecanoate
- thalidomide
- theophylline
- thiazide
- thiotepa: 1-10%
- thyroxine
- tiagabine: frequent
- timolol
- tizanidine: infrequent
- tolcapone: 1%
- topiramate: postmarketing, rare, 0% - 6.3%
- topotecan: very common, 0% - 54%
- toremifene
- trabectedin
- trandolapril: postmarketing
- trandolaprilat: postmarketing
- tranylcypromine
- trazodone: postmarketing
- trimethadione
- trimipramine
- v 1784: postmarketing, 0% - 4%
- valdecoxib
- valganciclovir
- valproate: 2.4% - 24%
- valsartan: postmarketing
- vandetanib: 8%
- vemurafenib: postmarketing, 0% - 45%
- venlafaxine: postmarketing, infrequent, uncommon
- verapamil: postmarketing
- vinblastine
- vincristine
- vinflunine
- vinorelbine: 0% - 30%
- vismodegib: 63.8% - 65.2%
- voriconazole: common
- vorinostat
- warfarin
- zalcitabine
- zaleplon: infrequent
- zidovudine/lamivudine: postmarketing
- ziprasidone: rare, infrequent
- zoledronic acid
- zonisamide: infrequent
- zopiclone: infrequent
|
Drugs with this indication
|